VitaDX

Based in France, VitaDX is a medical technology company specializing in in vitro diagnostic solutions for bladder cancer detection, utilizing advanced artificial intelligence and image processing. Founded in 2015 in Rennes, France, VitaDX develops diagnostic medical devices. The company offers innovative solutions for bladder cancer detection, a critical area in medical diagnostics. The firm has engaged in two significant funding rounds, including a recent deal in August 2025 where it raised EUR 1.

5 million from Go Capital and Odyssee Venture, totaling EUR 1. 5 million raised to date. No changes in business operations or strategy have been noted. VitaDX's core offering is its flagship product, VisioCyt® Bladder, a clinically validated in vitro diagnostic medical device that detects bladder cancer through a simple urine sample.

This advanced solution utilizes artificial intelligence and image processing technology developed from extensive research at the Institut des Sciences Moléculaires d'Orsay. VisioCyt® Bladder has received CE IVDR certification and became available for prescription in early 2023, targeting healthcare providers, including pathology laboratories and urology clinics, across Europe, particularly in regions with high incidences of bladder cancer. VitaDX generates revenue by supplying its VisioCyt® Bladder diagnostic solution to healthcare institutions. Utilizing a direct-to-consumer model, healthcare providers acquire the product for their diagnostic needs, with key partners like Médipath and XPath facilitating its integration into clinical settings.

Revenue transactions are structured through agreements with these partners, highlighting the growing demand for advanced cancer diagnostic technologies among hospitals and clinics. In August 2025, VitaDX secured EUR 1. 5 million in venture funding to enhance its commercial rollout in France and prepare for market entry into the US. The company aims to launch new products designed for bladder cancer detection, with specific timelines for expansion in targeted regions.

The funding will support these strategic initiatives, enabling VitaDX to pursue growth in new geographic markets.